| 标题 |
Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet HIV 作者:Juergen Rockstroh; Sheetal Kassim; Roger Paredes; Christopher Bettacchi; Gary I Sinclair; et al 出版日期:2026-02-01 |
| 求助人 | |
| 下载 | 暂无链接,等待应助者上传 |
PDF的下载单位、IP信息已删除
(2025-6-4)